Home » Clinical Trials » Solid tumors » NCT05382377
NCT05382377

A Single-center, Open-label, Single-arm Clinical Study of the Safety and Efficacy of KD-025 CAR-T Therapy in Advanced NKG2DL+ Solid Tumors

Study Summary

This is a Phase 1, single-arm, single-center, open-label study to evaluate the safety and effectiveness of NKG2D-based CAR-T cells infusion in the treatment of advanced NKG2DL+ solid tumors.

Want to learn more about this trial?

Request More Info

Interventions

KD-025BIOLOGICAL
Autologous genetically modified anti-NKG2DLs CAR transduced T cells

Study Locations

FacilityCityStateCountry
Chinese PLA General HospitalBeijingBeijing MunicipalityChina

Official Trial Information

View on ClinicalTrials.gov

Data sourced from ClinicalTrials.gov. Last updated: April 14, 2026